Originally appearing here.
Summary: The New York Times reports on the newly published results of MAPS’ U.S. Food and Drug Administration (FDA)-regulated clinical trial of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD) in veterans, firefighters, and police officers. The New York Times speaks with MAPS-sponsored MDMA researcher Michael Mithoefer, M.D., and trial participants Nigel McCourry and Nicholas Blackston.
“The MDMA alone or the therapy alone don’t appear to be as effective,” explains Mithoefer. “The MDMA seems to act as a catalyst that allows the healing to happen.”
“I was actually able to forgive myself,” explains McCourry. “There are also still some challenges I have to face from time to time related to the PTSD. But now I am able to work through them without getting stuck.”